Latest filing published 12 Jan 2026 for AKTIS ONCOLOGY, INC.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Lloyd Mitchell Segal (chief executive) discloses dealings in 2 companies, chiefly Repare Therapeutics Inc. and Aktis Oncology, Inc. In total, 12 filings cover trades dated from 18 May 2021 to 12 January 2026.
The open-market record consists of 8 sales worth €470k, with no purchase. Outside the open market, there are 3 share grants.
Most recently, on 12 January 2026, the filings show a transaction in Aktis Oncology, Inc. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
12 of 12 declarations